Skip Navigation


NDT Advance Access originally published online on August 2, 2007
Nephrology Dialysis Transplantation 2007 22(10):2768-2774; doi:10.1093/ndt/gfm525
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/10/2768    most recent
gfm525v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Korantzopoulos, P.
Right arrow Articles by Milionis, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korantzopoulos, P.
Right arrow Articles by Milionis, H. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease—ready for prime time?

Panagiotis Korantzopoulos1, Moses Elisaf2 and Haralampos J. Milionis2

1Department of Cardiology and 2Department of Internal Medicine, School of Medicine, University of Ioannina, 451 10 Ioannina, Greece

Correspondence to: Panagiotis Korantzopoulos, MD, Department of Cardiology, School of Medicine, University of Ioannina, 451 10 Ioannina, Greece. Email: p.korantzopoulos@yahoo.gr

Keywords: cardiovascular risk; chronic kidney disease; intensive therapy; metabolic syndrome; multifactorial treatment; renal failure

The first 150 words of the full text of this article appear below.

The term metabolic syndrome (MetSyn) indicates a constellation of risk factors associated with increased burden of atherosclerotic disease [1]. Despite some controversy regarding its existence as a distinct entity [2], accumulating evidence suggests that individuals with MetSyn are at increased risk of cardiovascular events and type 2 diabetes [3,4]. Several factors such as obesity, insulin resistance, physical inactivity and advancing age seem to constitute its pathophysiological basis [1,5]. The prevalence of MetSyn depends on the studied population and the definition used but in Western populations more than 20% of adults are affected [6]. Current ‘popular’ definitions of MetSyn, such as that of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III, the National Heart, Lung, and Blood Institute and the American Heart Association (NHLBI/AHA) and especially that proposed by the International Diabetes Federation (IDF) . . . [Full Text of this Article]



   Metabolic syndrome and chronic kidney disease
 


   CKD and cardiovascular disease
 


   Importance of CKD prevention in MetSyn
 


   Multifactorial intervention in MetSyn and CKD prevention
 
Drawbacks and Concerns


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?